Summit Therapeutics Inc. Cash Flows From Used In Financing Activities
Summit Therapeutics Inc. (SMMT) reported Cash Flows From Used In Financing Activities of -GBP 45.00 thousand for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Cash Flow › Financing Activities
ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2020-06-02
- Summit Therapeutics Inc. cash flows from used in financing activities for the quarter ending 2020-03-31 was -45.00K GBP.
- Summit Therapeutics Inc. cash flows from used in financing activities for the quarter ending 2019-10-31 was -89.00K GBP.
- Summit Therapeutics Inc. cash flows from used in financing activities for the quarter ending 2019-07-31 was -90.00K GBP.
- Summit Therapeutics Inc. cash flows from used in financing activities for the quarter ending 2019-04-30 was -88.00K GBP, a 100.62% decline year-over-year.
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 3 month as first filed | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 6 month as first filed | Cash Flows From Used In Financing Activities 9 month | Cash Flows From Used In Financing Activities 9 month as first filed | Cash Flows From Used In Financing Activities 11 month | Cash Flows From Used In Financing Activities 12 month | Cash Flows From Used In Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | -45.00K GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-12-31 | 37.70M GBP 20-F · filed 2020-04-30 | ||||||||
| 2019-10-31 | -89.00K GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | -179.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | -267.00K GBP 6-K · filed 2019-12-17 | ||||||
| 2019-07-31 | -90.00K GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | -178.00K GBP 6-K · filed 2019-10-11 | |||||||
| 2019-04-30 | -88.00K GBP 6-K · filed 2019-06-12 | ||||||||
| 2019-03-31 | 19.10M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-01-31 | 19.11M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 19.03M GBP derived: sum of 2 quarters · filed 2020-04-30 | 18.96M GBP derived: sum of 3 quarters · filed 2020-04-30 | 33.11M GBP 20-F · filed 2020-04-30 | 33.44M GBP 20-F · filed 2019-03-29 | ||||
| 2018-10-31 | -79.00K GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | -153.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | 14.00M GBP 6-K · filed 2019-12-17 | 14.24M GBP 6-K · filed 2018-12-11 | 13.86M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-07-31 | -74.00K GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | 14.08M GBP 6-K · filed 2019-10-11 | 14.24M GBP 6-K · filed 2018-09-20 | 13.93M GBP derived: sum of 3 quarters · filed 2020-04-30 | 27.80M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-04-30 | 14.16M GBP 6-K · filed 2019-06-12 | 14.24M GBP 6-K · filed 2018-06-05 | 14.01M GBP derived: sum of 2 quarters · filed 2020-04-30 | 27.88M GBP derived: sum of 3 quarters · filed 2020-04-30 | 27.90M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-01-31 | -149.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 13.72M GBP derived: sum of 2 quarters · filed 2020-04-30 | 13.74M GBP derived: sum of 3 quarters · filed 2020-04-30 | 13.76M GBP 20-F · filed 2020-04-30 | 13.90M GBP 20-F · filed 2018-04-13 | ||||
| 2017-10-31 | 13.87M GBP derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11 | 13.89M GBP derived: sum of 2 quarters · filed 2018-12-11 | 13.90M GBP 6-K · filed 2018-12-11 | ||||||
| 2017-07-31 | 21.00K GBP derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20 | 34.00K GBP 6-K · filed 2018-09-20 | |||||||
| 2017-04-30 | 13.00K GBP 6-K · filed 2018-06-05 | ||||||||
| 2017-01-31 | 413.00K GBP 20-F · filed 2019-03-29 | ||||||||
| 2016-01-31 | 22.14M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |